Showing 5301-5310 of 6662 results for "".
- Handheld Device May Painlessly Identify Skin Cancershttps://practicaldermatology.com/news/handheld-device-may-painlessly-identify-skin-cancers/2461188/Researchers at Stevens Institute of Technology are developing a low-cost handheld device that could cut the rate of unnecessary biopsies in half and give dermatologists and other frontline physicians easy access to laboratory-grade cancer diagnostics. “We aren’t trying
- DermTech Seeks to #Stickit2Melanomahttps://practicaldermatology.com/news/dermtech-seeks-to-stickit2melanoma/2461184/DermTech is bringing back its #Stickit2Melanoma campaign in honor of Melanoma and Skin Cancer Awareness Month. First launched in 2021, the campaign supports DermTech’s core mission to help end deaths from melanoma through early and reliable detection. For every
- Castle Biosciences Supports Patient-Focused Initiatives for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/castle-biosciences-supports-of-patient-focused-initiatives-for-skin-cancer-awareness-month/2461182/Castle Biosciences, Inc. will continue its ongoing collaboration with the Melanoma Research Foundation (MRF) and The Skin Cancer Foundation to support skin cancer research, education and advocacy, highlighting events during May, in recognition of Skin Cancer Awareness Month. “We a
- Pathologist Survey: Melanoma Is Overdiagnosedhttps://practicaldermatology.com/news/pathologist-survey-melanoma-is-overdiagnosed/2461180/Many pathologists agree that overdiagnosis of skin cancer happens, but don’t change diagnosis behavior, according to a new study. “Overdiagnosis is the diagnosis of disease that will not harm a person in their lifetime. If melanoma is being overdiagnosed, it means that too m
- Ready for Prime Time? Ampel’s Blood Tests May Predict Drug Options for Inflammatory Skin Diseasehttps://practicaldermatology.com/news/ready-for-prime-time-ampels-blood-tests-may-predict-drug-options-for-inflammatory-skin-disease/2461179/Ampel BioSolutions machine learning approach can characterize disease activity from gene expression data obtained from patient skin biopsy and may revolutionize the way doctors treat inflammatory skin diseases, according to research published in Science Advances. The lab test
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn
- New Colorescience, Aesthetics Biomedical Collabhttps://practicaldermatology.com/news/new-colorescience-aesthetics-biomedical-collab/2461177/Colorescience and Aesthetics Biomedical are launching a collaboration that combines Vivace Microneedle RF with a post-treatment protocol featuring Colorescience’s Sunforgettable Total Protection Brush-On Shield SPF 50. Patients opting for the radiofrequency microneedlin
- Chicago Dermatological Society to Host Art of Skin Gala to Advance Diversity, Equity, and Inclusionhttps://practicaldermatology.com/news/chicago-dermatological-society-to-host-art-of-skin-gala-to-advance-diversity-equity-and-inclusion/2461176/The Chicago Dermatological Society (CDS) is launching the Art of Skin Gala, sponsored by Janssen Biotech, Inc. The event, to be held June 10, is described as a live, in color celebration of diversity, equity, and inclusion brought to life through the beauty of skin. The
- ePatch Using Electrical Field Stimulation Shows Promise for Wound Healinghttps://practicaldermatology.com/news/epatch-using-electrical-field-stimulation-shows-promise-for-wound-healing/2461175/A “smart” flexible electric patch (ePatch) developed by a collaborative team from the Terasaki Institute for Biomedical Innovation promises to address the challenges posed by existing electrical field (EF) stimulation devices for wound healing and offers many uniquely advantageous fea
- FDA Approves Sol-Gel Technologies' and Galderma's Epsolay for Rosaceahttps://practicaldermatology.com/news/fda-approves-sol-gel-technologies-and-galdermas-epsolay-for-rosacea/2461170/The FDA has approved Sol-Gel Technologies' Epsolay, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults. The benzoyl peroxide in Epsolay is encapsulated within silica-based patented microcapsules. The silica-based s